Event overview
The strategy highlights the importance of developing adverse outcome pathways (AOPs) and integrated approaches to testing and assessment (IATA) related to acute systemic toxicity. It also discusses improvements in the predictability of the 3T3 NRU assay, development of additional in vitro and in silico approaches, waiving acute toxicity testing based on e.g., repeated dose data, refinement of in vivo studies, and provides a framework for prioritizing the alternative methods that have been submitted to EURL ECVAM for validation.
Following Dr. Prieto’s talk, Dr. Lawrence Milchak, Advanced Toxicology Specialist, 3M, will speak of industry experiences on the use of alternative strategies to meet acute toxicity testing requirements.